WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences solutions, announced today the availability of a new TGaS benchmarking assessment that identifies the high-risk functions within pharma that are least prepared for challenges generated by the COVID-19 pandemic.
Sales rep training, forecasting, competitive intelligence, patient support services and KOL relationship management are among the highest risk functions that need to consider significant evolution to adjust to a current and post-pandemic world.
“The COVID-19 crisis has all of us engaged with the U.S. healthcare system thinking about how the future may look different than our collective past,” said Gary McWalters, President of TGaS Advisors, a Division within Trinity. “With forward-looking ideas in mind, TGaS has considered the most likely changes within the pharmaceutical commercial model and assessed which commercial operations functional areas are most likely to be least prepared from a capabilities perspective for the challenges that lie ahead.”
The dashboard can be viewed: Impact of COVID-19 on Commercial Capabilities by Functional Area.
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.